Case Reports in Neurological Medicine / 2014 / Article / Fig 2

Case Report

Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion

Figure 2

(a, b) SMN immunoreactivity in fibroblasts obtained from the proband (scale bar = 10 μm): a faint (red) staining was present within nuclear structures (actin filaments counterstained in green) in vehicle-treated cells (VEH), while VPA 5 mM/72 h induced an apparent density increase of SMN-positive nuclear aggregates; (c) acetyl-histone H3 association with SMN promoter was increased in fibroblast obtained from the proband following exposure to VPA 5 mM/72 h, as semiquantified by ChIP assay ( ); (d) SMN-like immunoreactive content in fibroblasts obtained from the proband is increased following in vitro exposure to VPA, as semiquantified by Western blotting ( ); (e) (Western blotting) SMN-like immunoreactive content in fibroblasts obtained from 12 SALS patients is reduced with respect to 9 matched controls ( ), as also shown by (f) representative immunoreactive signals (10 μg of total protein) obtained in 5 different SALS patients and 4 CTRL subjects.
216094.fig.002a
(a)
216094.fig.002b
(b)
216094.fig.002c
(c)
216094.fig.002d
(d)
216094.fig.002e
(e)
216094.fig.002f
(f)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.